Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Subscribe To Our Newsletter & Stay Updated
